Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Panel Backs GSK Vaccine

By Drug Discovery Trends Editor | September 11, 2009

WASHINGTON (AP) – Federal health officials said a long-delayed vaccine from GlaxoSmithKline successfully blocks the leading virus that causes cervical cancer in women.

The Food and Drug Administration’s vaccine panel voted overwhelmingly that the vaccine Cervarix appears safe and effective for girls and women ages 10 to 25.

If the FDA follows the group’s advice, Glaxo would begin competing against Merck’s vaccine Gardasil, which has controlled the U.S. market since 2006.

London-based drugmaker Glaxo already has won approval for its vaccine in Europe, but its U.S. launch was delayed in 2007 when the FDA said it needed more data about the vaccine.

Panelists say newer studies suggest the vaccine is safe, but they recommend follow-up studies to monitor miscarriages and inflammatory-muscular problems reported by a small number of patients.

The group said it was unlikely those problems were related to the vaccine, but said the issues should still be noted on the product labeling.

“This wasn’t a pregnancy trial and it wasn’t meant to be used in pregnancy, it just happened accidentally,” said Dr. Kenneth Noller, of Tufts University. “I think this could be marketed with the usual caveat that it’s not to be used in pregnancy.”

The human papilloma virus, or HPV, infects about 6 million people in the U.S. each year, and is mainly spread through sexual contact. It usually doesn’t carry any symptoms and goes away within two years, but rare cases can develop into warts and cancers in both men and women.

Last year, nearly 4,000 women died of cervical cancer in the U.S., less than 1 percent of all cancer-related deaths.

Even if the FDA grants approval, Glaxo will face an uphill battle against Merck’s Gardasil, which has had the U.S. market to itself for the last three years. Besides an established brand, Gardasil also boasts an extra degree of protection against sexually transmitted diseases.

Gardasil and Cervarix both defend against HPV strains 16 and 18, which cause about 70 percent of cervical cancer cases. But Merck’s vaccine also defends against two other HPV types that cause 90 percent of genital warts, something Cervarix does not target.

Leerink Swan analyst Seamus Fernandez estimates Glaxo’s Cervarix will eventually make up 25-30 percent of the total market for HPV-blocking vaccines. Cervarix global sales were $231 million last year.

Even as the British drugmaker moves closer to competing in the U.S., Whitehouse Station, N.J.-based Merck is seeking approval to begin marketing Gardasil to boys and men.

The panel is scheduled to vote later Wednesday on Gardasil as a preventive measure against genital warts in males.

Date: September 9, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE